Abstract Details

Title Impact of 'Achieving Minimal Manifestations or Better Status with Prednisolone ?5 mg/day' in MG Patients on Self-Perceived Quality of Life: A Multicenter Follow-Up Study

Topic Muscle Disease/Neuromuscular Junction

Presentation(s) P02 - (-)

Poster/Presentation
Number 202

Objective

Background BACKGROUND: In our first survey in 2010, we verified the Japanese version of the 15-item MG-specific QOL scale (MG-QOL15-J) and assessed associations with clinical factors. Low MG-QOL15-J scores (i.e., good QOL) were shown for patients achieving MG Foundation of America (MGFA) minimal manifestation (MM) status on ?5 mg prednisolone/day. The MG-QOL15-J scores were comparable to those in patients with MGFA complete stable remission (CSR) status and given that it is uncommon for MG patients to achieve CSR, achieving MM or better status with prednisolone ?5 mg/day was tentatively identified as a practical treatment target. These issues should be further examined in longitudinal studies.

Design/Methods DESIGN/METHODS: In this survey, we evaluated 640 consecutive MG patients (Japan MG registry, 11 neurological centers), including the 275 patients reported in the first survey. All patients completed the MG-QOL15-J. Disease severity was assessed using the MGFA quantitative MG (QMG) and the MG composite (MGC) scores. Clinical state following treatment was categorized according to MGFA postintervention status.

Results RESULTS: Mean decreases in MGC score (5.4±5.4 to 4.3±5.1), QMG score (6.9±4.9 to 6.7± 5.0), and prednisolone dose (4.1±6.1 to 3.4±4.3 mg/day) during the 2-year follow-up were modest. Mean improvement in MG-QOL15-J score was 2.5±6.0. The proportion of patients with MM or better status with prednisolone ?5 mg/day increased significantly (41.5% to 52.4%). Multivariate analysis revealed that a decrease in MGC but not QMG score and newly achieving MM or better status with prednisolone ?5 mg/day were significant factors in improving MG-QOL15-J score.

Conclusions CONCLUSIONS: Achieving status of MM or better with prednisolone ?5 mg/day has a positive impact on QOL improvement in MG patients and can be recommended as a treatment target.

Authors/Disclosures
Yuriko Nagane, MD, PhD (Hanamaki General Hospital, Neurology Dept) PRESENTER	No disclosure on file
Kimiaki Utsugisawa, MD, PhD (Hanamaki General Hospital)	Dr. Utsugisawa has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for argenx. Dr. Utsugisawa has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB pharma. Dr. Utsugisawa has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen pharma. Dr. Utsugisawa has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Viela Bio. Dr. Utsugisawa has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Chugai. Dr. Utsugisawa has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Mitsubisi Tanabe pharma. Dr. Utsugisawa has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Utsugisawa has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for argenx. Dr. Utsugisawa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion phama. Dr. Utsugisawa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Japan Blood Products Organization. Dr. Utsugisawa has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB.
	No disclosure on file
Masayuki Masuda	Masayuki Masuda has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Alexion pharma, Argenix pharma, Aasahi kasei pharma, UCB, Takeda pharma.
	No disclosure on file
Yasushi Suzuki, MD, PhD (Tohoku Univericity)	No disclosure on file
Kazuo Fujihara, MD (Tohoku University, School of Medicine)	Dr. Fujihara has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Fujihara has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck Boipharma. Dr. Fujihara has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Japan Tobacco. Dr. Fujihara has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Fujihara has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Mitsubishi-Tanabe. Dr. Fujihara has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Chugai/Roche. Dr. Fujihara has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Fujihara has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Fujihara has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Fujihara has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. The institution of Dr. Fujihara has received research support from Ministry of Health, Welfare and Labor of Japan. Dr. Fujihara has received personal compensation in the range of $10,000-$49,999 for serving as a speaker, chair, etc with Novartis. Dr. Fujihara has received personal compensation in the range of $5,000-$9,999 for serving as a speaker, chair, etc with Biogen. Dr. Fujihara has received personal compensation in the range of $10,000-$49,999 for serving as a speaker, chair, etc with Mitsubishi-Tanabe. Dr. Fujihara has received personal compensation in the range of $10,000-$49,999 for serving as a apeaker, chair, etc with Chugai/Roche. Dr. Fujihara has received personal compensation in the range of $500-$4,999 for serving as a speaker, chair, etc with Alexion. Dr. Fujihara has received personal compensation in the range of $500-$4,999 for serving as a chair, speaker with Asahi Kasei Medical. Dr. Fujihara has received personal compensation in the range of $500-$4,999 for serving as a speaker with Eisai. Dr. Fujihara has received personal compensation in the range of $500-$4,999 for serving as a speaker, chair with Teijin.
Norihiro Suzuki	No disclosure on file

��ɫ��

��ɫ��